ReLink is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge today for patients receiving hospital and home infusions.
Our first product ReLink Care is CE approved and available for sale.
The patented ReLink platform technology ensures delivery of critical fluids safely and efficiently.
ReLink® by Tada Group AB
Our focus is to develop and commercialise intuitive products designed for unmet clinical needs that add superior value to the healthcare system.
ReLink®- a breakaway connector for IV lines
The problem with Intravenous (IV) therapy
Intravenous (IV) therapy is the most common invasive procedure in modern healthcare, with fluids delivered directly into the vein through tubing connected to a catheter device.
Research shows that around 16.6 billion tubes(1) are being used across the world today and ~10% of tubes are forcefully ripped from the vein during infusions(2). However, the problem is more serious than that. The PIVC failure rates and complication incidences are so high that approximately 1 out of every 2 catheters fail to make it to 5 days or to the end of treatment(3).
IV catheters are prone to mechanical complications such as phlebitis, infiltration and dislodgement resulting in catheter failure that happens at an alarming rate of 46%(4).
This IV catheter failure can result in injury to patients, loss of fluid resources, exposure of hazardous drugs and increased risk of infection. It also creates additional work for clinicians, with up to 18-44 mins of additional time required to clean and reinstate the infusion(5).
Infusion stability with ReLink
ReLink is a breakaway connector, designed and engineered to increase safety, accuracy, and efficiency of IV therapy in healthcare settings.
Its unique design features double-sided, self-sealable valves, with weak link activation to protect the catheter placement site and prevent loss of fluid resources. The pull force required to separate the tube from the catheter has been optimised through rigorous testing to ensure the catheter dwelling site remains protected.
After separation, both ReLink connector parts can be simply disinfected and reconnected for rapid reinstatement of therapy, providing unrivalled efficiency for nursing staff in every environment.
ReLink is specially engineered to enhance infusion stability by keeping connections of IV catheters to the patients with a controlled break away and predictable results.
Hover over ReLink
ReLink® product family
ReLink is a platform technology which is adaptable across a broad range of sectors...
ReLink Care
First generation single use breakaway connector for increased safety for patient and healthcare professionals. CE approved for gravitational IV.
Hover over the image
ReLink Veterinary
Annual market value of €35 billion in Europe and USA. Low regulatory barrier for market entry. No product modifications required for treatment of small animals.
Hover over the image
ReLink Advanced
Next generation connector for pump driven infusions. Designed to meet the needs of all patient groups and be compatible with all IV fluids including blood and blood products.
Hover over the image
ReLink Digital
Moving IV therapy from the hospital to the home could save up to 90% of treatment costs. Continuity of care is enabled by including electronics for monitoring and communication.
Hover over the image
Closed System
A closed system connector device that eliminates leakage of toxic liquids and vapours to safekeep healthcare professionals working with hazardous drugs such as chemotherapy.
Hover over the image
Antimicrobial
Breakaway connector with a functionalised surface for antimicrobial protection. Especially beneficial for immunocompromised patients and central line usage.
Hover over the image
Meet the team
Katarina Hedbeck
Chief Executive Officer
& Co-founder
Dr. Rebecca Bejhed
Chief Operating Officer
& Co-founder
Christopher Blacker, MD
Medical Lead
& Co-founder
Chief Technical Officer
Pallavi Saksena
Maria Asif
Chief Financial Officer
Puneet Gaharana
Chief Strategy Officer
Dr. Ujala Bhardwaj
Chief Quality Officer
Design Manager
News
A snapshot of what's keeping us inspired, excited and busy!
Follow us on:
The project has received funding from the European Union's Horizon 2020 research and innovation programme under EIC Accelerator grant agreement No 961967, Fast Track to Innovation grant No 971225 and from the Eurostars-2 Joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme.
References
-
Literature study data
-
Chopra, V. et al. Peripherally inserted central catheter use in skilled nursing facilities: a pilot study. J. Am. Geriatr. Soc. 63, 1894–1899 (2015).
-
Steere, L., Ficara, C., Davis, M., & Moureau, N. (2019). Reaching one peripheral intravenous catheter (PIVC) per patient visit with lean multimodal strategy: the PIV5Rights™ bundle. Journal of the Association for Vascular Access, 24(3), 31-43.
-
Treffalls, J. A., Portillo, D. J., Friesenhahn, S., Copeland, G. B., & Hood, R. L. (2021). The Occurrence of Peripheral Intravenous Catheter Complications and an Evaluation of the Methods Utilized to Mitigate Them. J Nurs Patient Health Care, 3(1), 102.
-
Literature study data
The project has received funding from EIT Health.